PsiOxus, the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first… read more →
March 13, 2019 – OXFORD, UK – PsiOxus Therapeutics Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started dosing NG-350A, an antibody based cancer gene… read more →
A fantastic article in Endpoint News about the collaboration between PsiOxus and the Parker Institute for Cancer Immunotherapy.
Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at… read more →
December 12, 2017 –OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has… read more →
(OXFORD, United Kingdom and PHILADELPHIA, United States. 16th August 2017) PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as… read more →